生物活性含鍶之矽酸鈣骨水泥促進人類間質幹細胞成骨作用評估

近年來的統計發現全世界約有九百萬人因為骨質疏鬆症導致相關的骨折傷 害，並且在目前人口的發展速度下可以預測這一類的病人會越來越多。骨質疏鬆 症是一項全身性的疾病，原因來自於體內成骨細胞與蝕骨細胞的平衡被破壞，進 而導致骨密度的下降以及骨頭微結構的退化。在臨床上，這一類的病人所需要的 骨頭取代物除了需具備原有可被吸收的特性外，更希望可以進一步抑制蝕骨細胞 的分化。在臨床上，鍶已被證明會透過鈣離子通道來抑制成熟蝕骨細胞的分化及 活性，並且已被廣泛的應用於骨質疏鬆的治療。過去本實驗室開發的矽酸鈣材料 的由於降解速度太慢，導致降低其骨傳導性的特點，這會大大限制了該材料在臨 床上的使用。因此，在本研究中分別利用高溫燒結法以及溶膠凝膠法來製備出含 有不同鍶比例的矽酸鈣粉末，並且評估細胞培養不同成分材料上的改變。結果顯 示，含鍶的矽酸鈣具有較好的機械性質，並仍保有原來的生物活性，能夠有效的 形成磷灰石層，以幫助骨頭再生。並且能夠提升 WJMSC 在材料表面的貼附、生 長及分化，在鹼性磷酸酶及骨鈣蛋白的表現上皆優於傳統的矽酸鈣。這些結果都 能夠顯示，將 Sr 混入 CS 陶瓷後，能夠有效刺激幹細胞進行骨分化的反應的。因 此我們認為 SrCS 陶瓷是一具有高度發展潛力、且可應用於骨組織工程的材料。

Materials with varying degrees of bioactivity and degradation are required so as to conform to differing clinical requirements for hard tissue repair. Autograft possesses all the characteristics indispensable for new bone formation, namely, osteogenesis, osteoconductivity, and osteoinductivity, and it is currently considered the gold standard in this field. In spite of its strengths, however, there are still various disadvantages when using this material for certain medical clinical applications. Therefore, the design of an even better composite material would be very beneficial for controlling material physicochemical properties. Thus, the bone substitute materials are required to support the bone remodeling process, which consists of osteoclastic resorption and osteoblastic synthesis. Recently, several studies have indicated that calcium silicate (CS) can play an important role in bone formation, at least based upon these materials’ patterns of Si ion release and its fast apatite formation ability. However, the slow degradation rate of CS may result in a decrease in osteoconductivity, which may limit its clinical application. The aim of this project was development of strontium-calcium silicate (Sr- CS) cement is potentially favorable for promoting bone regeneration and repair. The study indicated that the incorporation of Sr into CS powder is a viable way to enhance the biological behavior of WLMSCs. SrCS cement are a promising bioactive material for tissue-engineering applications in the clinic.